Erez Berman

Erez Berman

Auto-generated profile, based on publicly available information

Erez Berman

Institute for Drug Research, School of Pharmacy, Faculty of Medicine Hebrew University of Jerusalem Jerusalem Israel

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2017 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
EBErez Berman
Erez Berman
SESara Eyal
Sara Eyal
EMEli Marom
Eli Marom

1 August 2016 in Epilepsy & Behavior
Verified
Journal Article
Closed access
EBErez Berman
Erez Berman
EMEli Marom
Eli Marom
DEDana Ekstein
Dana Ekstein
IBIlan Blatt
Ilan Blatt
SESara Eyal
Sara Eyal

29 December 2021 in Epilepsia
Verified
Journal Article
Closed access
PDF file
EBErez Berman
Erez Berman
INIris Noyman
Iris Noyman
MMMordekhay Medvedovsky
Mordekhay Medvedovsky
DEDana Ekstein
Dana Ekstein
SESara Eyal
Sara Eyal

16 October 2023 in Epilepsia
Verified
Journal Article
Open access
EBErez Berman
Erez Berman
NENatalia Erenburg
Natalia Erenburg
RBRon Beloosesky
Ron Beloosesky
SESara Eyal
Sara Eyal
Michal KovoMichal Kovo
Michal Kovo
Objective: In the absence of safety data in humans, the use of cannabidiol (CBD) is not recommended during pregnancy. Yet >50% of pregnancies in women with epilepsy are unintended, making fetal exposure to CBD possible. As a small‐molecule, highly lipid‐soluble drug, CBD is likely to be distributed into the placenta and cross it. To estimate the placental distribution profile of CBD and its potential short‐term placental effects, we conducted an ex vivo perfusion study in human placentas.Methods: Placentas were obtained from healthy women undergoing cesarean deliveries. Selected cotyledons were cannulated and perfused for 180 min with a CBD‐containing medium (250 ng/mL, .796 μmol·L−1; representative of a low therapeutic concentration; n = 8). CBD concentrations were determined at 180 min in the medium and placental tissue using liquid chromatography–tandem mass spectrometry. A customized gene panel array was used to analyze the expression of selected genes in the perfused placental cotyledons as well as in placentas perfused with 1000 ng/mL CBD (3.18 μmol·L−1; high therapeutic concentration; n = 8) and in those exposed to the vehicle.Results: CBD was sequestered in the placental tissue, exhibiting significant variability across samples (median = 5342 ng/g tissue, range = 1066–9351 ng/g tissue). CBD concentrations in the fetal compartment were one fifth of those measured in the maternal compartment (median = 59 ng/mL, range = 48–72 ng/mL vs. 280 = ng/mL, range = 159–388 ng/mL, respectively; p < .01). Placental gene expression was not significantly altered by CBD.Significance: The placenta acts as a depot compartment for CBD, slowing down its distribution to the fetus. This phenomenon might yield flatter but prolonged fetal CBD levels in vivo. The attenuated transplacental CBD transfer does not imply that its use by pregnant women is safe for the fetus. Only pregnancy registries and neurocognitive assessments would establish the risk of being antenatally exposed to CBD.

3 September 2022 in Epilepsia
Verified
Journal Article
Open access
EBErez Berman
Erez Berman
EKElkana Kohn
Elkana Kohn
MBMatitiahu Berkovitch
Matitiahu Berkovitch
Michal KovoMichal Kovo
Michal Kovo
SESara Eyal
Sara Eyal
Objective: Lacosamide is increasingly being prescribed to pregnant women, although its effects on the developing fetus have not been fully clarified yet. Previously, we have shown that several antiseizure medications, particularly valproate, can affect the expression of carriers of essential compounds in placental cells. Here, our aim was to assess the effect of short ex vivo exposure of human placentas to lacosamide on the expression of carriers of essential nutrients required by the human fetus.Methods: Placentas were obtained from cesarean deliveries of women with no known epilepsy. Cotyledons were cannulated and perfused over 180 min in the presence of lacosamide at 2.5 μg/ml (10 μmol·L−1, n = 7) or 10 μg/ml (40 μmol·L−1, n = 6), representing low and high therapeutic concentrations, respectively, in the maternal perfusate. Valproate (83 μg/ml, 500 μmol·L−1, n = 6) and the perfusion solution (n = 6) were used as the respective positive and negative controls. A customized gene panel array was used to analyze the expression of carrier genes in the perfused cotyledons.Results: Following a 3‐h perfusion, the mRNA expression of SLC19A1 (encoding the reduced folate carrier 1) was downregulated in placentas treated with 10 μg/ml lacosamide (50%) as compared with the vehicle (p < .05). Across all groups, a significant difference was observed in the expression of SLC19A3 (thiamine transporter 2; 52%, 20%, and 9% decrease by 10 μg/ml lacosamide, 83 μg/ml valproate, and 2.5 μg/ml lacosamide, respectively; p < .05).Significance: Lacosamide at high therapeutic concentrations exerted pharmacological effects on the human placenta. Our findings, if manifested in vivo, suggest that lacosamide could potentially affect folate supply to the fetus and support therapeutic monitoring and careful adjustment of lacosamide plasma concentrations during pregnancy.